EPIGENOMICS AG Inactive Instrument
Epigenomics AG Stock Xetra
Equities
DE000A1K0516
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - EUR | - |
|
| Apr. 30 | Epigenomics AG Announces Jens Ravens Leaves as Executive Board Member | CI |
| Mar. 14 | Epigenomics AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 485K 527K | Sales 2023 | 339K 369K | Capitalization | 1.59M 1.72M |
|---|---|---|---|---|---|
| Net income 2022 | -12M -13.04M | Net income 2023 | -4M -4.35M | EV / Sales 2022 | -5.22 x |
| Net cash position 2022 | 9.28M 10.09M | Net Debt 2023 | 9.78M 10.63M | EV / Sales 2023 | 33.5 x |
| P/E ratio 2022 |
-0.56
x | P/E ratio 2023 |
-0.36
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 66.77% |
More Fundamentals
* Assessed data
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Frederic Hilke
IRC | Investor Relations Contact | - | - |
Annett Dietrich
HRO | Human Resources Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Helge Lubenow
CHM | Chairman | 56 | 16-05-24 |
Jochen Hummel
BRD | Director/Board Member | 54 | Feb. 04 |
Alexander Link
BRD | Director/Board Member | 53 | 20-05-31 |
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Calendar
2024-09-29
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -39.39% | 8.36B | |
| +10.79% | 3.38B | |
| +3.81% | 2.18B | |
| -25.96% | 1.82B | |
| -17.96% | 1.64B | |
| +31.30% | 1.03B | |
| +31.42% | 752M | |
| -12.01% | 689M | |
| -20.61% | 516M |
